Incidence, characterization, and clinical impact analysis of peginterferon beta1a immunogenicity in patients with multiple sclerosis in the ADVANCE trial

Incidence, characterization, and clinical impact analysis of peginterferon beta1a immunogenicity in patients with multiple sclerosis in the ADVANCE trial

Background: Efficacy of interferon beta in multiple sclerosis (MS) can be dampened in patients who develop neutralizing antidrug antibodies (NAbs). Peginterferon beta1a is an interferon conjugated with a polyethylene glycol (PEG) moiety. Pegylation increases a drug’s half life and exposure, and may...

Full description

Bibliographic Details
Main Authors:	Joleen T. White, Scott D. Newsome, Bernd C. Kieseier, Robert A. Bermel, Yue Cui, Ali Seddighzadeh, Serena Hung, Mary Crossman, Meena Subramanyam
Format:	Article
Language:	English
Published:	SAGE Publishing 2016-07-01
Series:	Therapeutic Advances in Neurological Disorders
Online Access:	https://doi.org/10.1177/1756285616633967

Similar Items

Peginterferon beta-1a reduces disability worsening in relapsing–remitting multiple sclerosis: 2-year results from ADVANCE
by: Scott D. Newsome, et al.
Published: (2017-01-01)

Long-term outcomes of peginterferon beta-1a in multiple sclerosis: results from the ADVANCE extension study, ATTAIN
by: Scott D. Newsome, et al.
Published: (2018-08-01)

An update on the evidence base for peginterferon β1a in the treatment of relapsing–remitting multiple sclerosis
by: Pavan Bhargava, et al.
Published: (2016-11-01)

[Budget impact analysis for peginterferon beta-1a in relapsing remitting multiple sclerosis in Italy]
by: Sergio Iannazzo, et al.
Published: (2016-07-01)

[Cost-effectiveness analysis of peginterferon beta-1a in Italian relapsing remitting multiple sclerosis management]
by: Sergio Iannazzo, et al.
Published: (2016-07-01)

Peginterferon beta-1a – nowa postać interferonu beta-1a
by: Zdzisław Maciejek, et al.
Published: (2015-11-01)

Treatment satisfaction significantly improves in patients with multiple sclerosis switching from interferon beta therapy to peginterferon beta-1a every 2 weeks
by: Hendin B, et al.
Published: (2018-07-01)

An update on Peginterferon beta-1a Management in Multiple Sclerosis: results from an interdisciplinary Board of German and Austrian Neurologists and dermatologists
by: Annette Kolb-Mäurer, et al.
Published: (2019-06-01)

Cost-Effectiveness Analysis of Peginterferon Beta-1a in the Treatment of Relapsing-Remitting Multiple Sclerosis in Italy: Results of an Updated Analysis
by: Diego Centonze, et al.
Published: (2018-11-01)

Peginterferon beta-1a was associated with high adherence and satisfaction in patients with multiple sclerosis in a German real-world study
by: Til Menge, et al.
Published: (2021-03-01)

Defining a role for laquinimod in multiple sclerosis
by: Bernd C. Kieseier
Published: (2014-07-01)

Chemotherapeutics in the treatment of multiple sclerosis
by: Bernd C. Kieseier, et al.
Published: (2010-09-01)

Atacicept: targeting B cells in multiple sclerosis
by: Hans-Peter Hartung, et al.
Published: (2010-07-01)

Review: Innovative monoclonal antibody therapies in multiple sclerosis
by: Ralf A. Linker, et al.
Published: (2008-07-01)

Sustained virological response to treatment of chronic hepatitis C with peginterferon alfa and ribavirin
by: Junior André da Rosa, et al.
Published: (2012-06-01)

Towards the implementation of ‘no evidence of disease activity’ in multiple sclerosis treatment: the multiple sclerosis decision model
by: Martin Stangel, et al.
Published: (2015-01-01)

Individualizing HCV treatment with peginterferon and ribavirin: what needs to be done?
by: Donald M. Jensen
Published: (2009-01-01)

Danazol improves thrombocytopenia in HCV patients treated with peginterferon and ribavirin
by: Guillermo Cabrera Álvarez, et al.
Published: (2011-10-01)

Matching comparisons of therapeutic efficacy suggest better clinical outcomes for patients treated with peginterferon beta-1a than with glatiramer acetate
by: Thomas F. Scott, et al.
Published: (2021-01-01)

Bioequivalence of intramuscular and subcutaneous peginterferon beta-1a: results of a phase I, open-label crossover study in healthy volunteers
by: Yuan Zhao, et al.
Published: (2021-01-01)

Outcome Measures in Multiple Sclerosis
by: Robert Bermel, et al.
Published: (2014-01-01)

Incidence of therapy-related acute leukaemia in mitoxantrone-treated multiple sclerosis patients in Germany
by: Anke Stroet, et al.
Published: (2012-03-01)

Specific aspects of modern life for people with multiple sclerosis: considerations for the practitioner
by: Celia Oreja-Guevara, et al.
Published: (2014-03-01)

A Randomized Study of Peginterferon Lambda-1a Compared to Peginterferon Alfa-2a in Combination with Ribavirin and Telaprevir in Patients with Genotype-1 Chronic Hepatitis C.
by: Robert Flisiak, et al.
Published: (2016-01-01)

Superiority of peginterferon α-2a and ribavirin combination over peginterferon α-2a monotherapy in the management of hemodialysis patients with chronic Hepatitis C virus infection
by: Saeed M.G Al-Ghamdi, et al.
Published: (2017-01-01)

Role of the Immunogenic and Tolerogenic Subsets of Dendritic Cells in Multiple Sclerosis
by: Zhong-Xiang Xie, et al.
Published: (2015-01-01)

Regulation von G-beta-gamma-Untereinheiten durch Phosducin-ähnliche Proteine (PhLP)
by: Bermel, Christina Maria
Published: (2006)

Chronic HCV treatment with peginterferon-ribavirin and severe tuberculosis re-activation
by: Calza Leonardo, et al.
Published: (2010-05-01)

Is peginterferon and ribavirin therapy effective in Korean patients with chronic hepatitis C?
by: Young Kul Jung, et al.
Published: (2013-03-01)

Efficacy and Tolerability of Peginterferon α-2a and Peginterferon α-2b, Both plus Ribavirin, for Chronic Hepatitis C: A Meta-Analysis of Randomized Controlled Trials
by: Zongguo Yang, et al.
Published: (2013-01-01)

Treatment of severe pneumonia due to COVID-19 with peginterferon alfa 2a
by: Rania M. El-Lababidi, et al.
Published: (2020-01-01)

Psychosis during peginterferon-alpha2a and ribavirin therapy: case report
by: Lucas C. Quarantini, et al.

Clinical characteristics of chronic hepatitis B cured by peginterferon in combination with nucleotide analogs
by: Xuli Bao, et al.
Published: (2020-07-01)

Population pharmacokinetics of peginterferon α2a in patients with chronic hepatitis B
by: Jingfeng Bi, et al.
Published: (2017-08-01)

Daclatasvir and Peginterferon/Ribavirin for Black/African-American and Latino Patients with HCV infection
by: Maribel Rodriguez-Torres, et al.
Published: (2016-11-01)

Oral Tolerance Induction in Experimental Autoimmune Encephalomyelitis with Candida utilis Expressing the Immunogenic MOG35-55 Peptide.
by: Christoph Buerth, et al.
Published: (2016-01-01)

Differences in clinical outcomes among hepatitis C genotype 1-infected patients treated with peginterferon alpha-2a or peginterferon alpha-2b plus ribavirin: a meta-analysis
by: O&#39;Regan C, et al.
Published: (2012-02-01)

Beta-interferons in multiple sclerosis
by: Aggarwal Sourabh, et al.
Published: (2010-01-01)

The Predictive Factors for Favorable Outcomes of Peginterferon and Ribavirin Combination Therapy in HCV-Infected Patients
by: Javad Moayedi, et al.
Published: (2020-08-01)

Interstitial pneumonia associated to peginterferon alpha-2a: A focus on lung function
by: Arturo Cortés-Telles
Published: (2016-01-01)